A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.Boyu Hu, Susan O’Brien, Loretta J. Nastoupil et al.|Journal of Clinical Oncology|2024Cited by 19
Coexistence of t(2;14;11)(p16.1;q32;q23) and t(14;19)(q32;q13.3) chromosome translocations in a patient with chronic lymphocytic leukemiaGuang‐Ming Liu, Yuanyuan Liu, Mohamad Cherry et al.|Medicine|2017Cited by 0
Vispa-Cel, an Allogeneic Anti-CD19 CAR-T cell Therapy with a PD-1 Knockout, In Patients with relapsed/refractory B cell Non-Hodgkin Lymphoma (r/r B-NHL): Updated Results from the Antler Phase 1 Clinical TrialMehdi Hamadani, Susan O'Brien, Houston Holmes et al.|Transplantation and Cellular Therapy|2026Cited by 0